UBXN4

Across TCGA pan-cancer cohorts, UBXN4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated UBXN4 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher UBXN4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated UBXN4 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

SKCM, CHOL, and BLCA are the cancer types where UBXN4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	II,III,IV	0.058	0.708	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
BLCA	OS	Median	II,III,IV	1.000	0.410	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

UBXN4–SKCM (DFS)

Open the SKCM breakdown →